二肽基肽酶 4 抑制剂市场机会、成长动力、产业趋势分析和 2024 年至 2032 年预测

2023 年，全球二肽基肽酶 4 抑制剂市场估值为 113 亿美元，预计在预测期内复合年增长率为 3.5%。市场扩张主要是由于全球 2 型糖尿病盛行率不断上升，增加了对有效治疗方法的需求。 DPP-4 抑制剂正在成为治疗第 2 型糖尿病的首选，因为它们能够调节血糖水平，而不会引起体重增加或低血糖等明显副作用。这些抑制剂的作用是防止荷尔蒙分解，从而刺激胰岛素释放以响应进餐。

药物开发和新配方的进步也促进了市场的成长。製药公司正致力于开发具有更好功效和安全性的 DPP-4 抑制剂，并透过更持久的配方等创新来提高患者的依从性。联合疗法也出现了新的趋势，其中包括 DPP-4 抑制剂和其他抗糖尿病药物，从而提供更全面的血糖管理方法。从药物类型来看，市场分为沙格列汀、西他列汀、利格列汀、阿格列汀、维格列汀等。

2023年，西他列汀占最大市场份额，占40.4%。其在管理血糖方面的悠久历史，加上其广泛的可用性和成熟的品牌影响力，有助于巩固其主导地位。市场按药物类型进一步分类，包括品牌 DPP-4 抑制剂和仿製药 DPP-4 抑制剂。到 2023 年，品牌药物市场价值 79 亿美元，由于支持品牌药物有效性和安全性的广泛临床试验，该市场处于领先地位。

此细分市场受益于强大的分销网络以及医疗保健提供者和患者之间的信任。就分销管道而言，市场分为医院药房、零售药房和网路药房。由于对糖尿病专业护理的需求不断增长，医院药房预计将以 3.4% 的复合年增长率增长。北美在全球市场中占据主导地位，到2023 年将达到46 亿美元。年增长率成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 2 型糖尿病盛行率上升
    • 患者对口服药物的高度偏好
    • 联合治疗趋势增加
  • 产业陷阱与挑战
    • 其他抗糖尿病药物的可用性
    • DPP-4 抑制剂相关的副作用
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类型，2021 - 2032

• 主要趋势
• 西格列汀
• 沙格列汀
• 利格列汀
• 阿格列汀
• 维格列汀
• 其他药物类型

第 6 章：市场估计与预测：按药物类型，2021 - 2032 年

• 主要趋势
• 品牌化
• 通用的

第 7 章：市场估计与预测：按配销通路，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 8 章：市场估计与预测：按地区划分，2021 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• AstraZeneca plc
• Bristol Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Eli Lilly and Company
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Pfizer, Inc.
• Takeda Pharmaceuticals Company Limited
• Sanofi
• Sanwa Kagaku Kenkyusho Co., Ltd.

The Global Dipeptidyl Peptidase 4 Inhibitors Market was valued at USD 11.3 billion in 2023 and is expected to grow at a CAGR of 3.5% during the forecast period. The market expansion is largely driven by the increasing prevalence of type 2 diabetes worldwide, boosting demand for effective treatments. DPP-4 inhibitors are becoming a preferred choice for managing type 2 diabetes due to their ability to regulate blood sugar levels without causing significant side effects such as weight gain or hypoglycemia. These inhibitors work by preventing hormones' breakdown, which stimulates insulin release in response to meals.

Advancements in drug development and new formulations are also contributing to the market's growth. Pharmaceutical companies are focusing on creating DPP-4 inhibitors that offer better efficacy and safety, with innovations like longer-lasting formulations to improve patient adherence. There is also an emerging trend toward combination therapies that include DPP-4 inhibitors alongside other antidiabetic drugs, offering a more comprehensive approach to managing blood sugar. In terms of drug types, the market is divided into saxagliptin, sitagliptin, linagliptin, alogliptin, vildagliptin, and others.

In 2023, sitagliptin held the largest market share, accounting for 40.4%. Its long history of effectiveness in managing blood glucose, combined with its wide availability and established brand presence, has helped solidify its dominance. The market is further categorized by medication type, with branded and generic DPP-4 inhibitors. The branded segment was worth USD 7.9 billion in 2023 and leads the market due to extensive clinical trials supporting the efficacy and safety of branded drugs.

This segment benefits from strong distribution networks and trust among healthcare providers and patients. When it comes to distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies are expected to grow at a CAGR of 3.4%, driven by the increasing need for specialized diabetes care. North America dominated the global market, accounting for USD 4.6 billion in 2023. The region's market is projected to grow at a 3.4% CAGR, fueled by the rising incidence of type 2 diabetes, high obesity rates, and well-established healthcare infrastructure, especially in the U.S., where demand for DPP-4 inhibitors continues to rise.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of type 2 diabetes
    • 3.2.1.2 High patient preference for oral medications
    • 3.2.1.3 Increasing combination therapy trend
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Availability of other antidiabetic drugs
    • 3.2.2.2 Side effects associated with DPP-4 inhibitors
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Sitagliptin
• 5.3 Saxagliptin
• 5.4 Linagliptin
• 5.5 Alogliptin
• 5.6 Vildagliptin
• 5.7 Other drug types

Chapter 6 Market Estimates and Forecast, By Medication Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Branded
• 6.3 Generic

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AstraZeneca plc
• 9.2 Bristol Myers Squibb Company
• 9.3 Boehringer Ingelheim International GmbH
• 9.4 Eli Lilly and Company
• 9.5 Merck & Co., Inc.
• 9.6 Mitsubishi Tanabe Pharma Corporation
• 9.7 Novartis AG
• 9.8 Pfizer, Inc.
• 9.9 Takeda Pharmaceuticals Company Limited
• 9.10 Sanofi
• 9.11 Sanwa Kagaku Kenkyusho Co., Ltd.